2026 MaTOS GU | Session I | Liquid Biopsies: 2026 Updates
Overview
Dr. Schaffer highlighted biomarkers for PSMA therapy: SUV mean, scan discordance, TP53 mutations, and CtDNA predict outcomes; more studies needed.
Dr. Crawford emphasized biomarkers (PSA, 4K, SelectMDX) for early prostate cancer detection; PSA ≥1.5 flags risk; combine tests to guide care, avoid overtreatment.
Dr. Khan outlined NGS testing: germline (blood/saliva) for risk, somatic (tissue/CtDNA) for treatment; combine biospecimens to guide care.
Dr. McConkey highlighted liquid biopsies: CtDNA (plasma) tracks metastases, utDNA (urine) local disease; timing, levels, and clearance predict outcomes.
The panel discussed liquid biopsy/CtDNA limits and promise: need more data, better sensitivity, repeat testing, and AI integration to guide therapy decisions.
Dr. Crawford emphasized biomarkers (PSA, 4K, SelectMDX) for early prostate cancer detection; PSA ≥1.5 flags risk; combine tests to guide care, avoid overtreatment.
Dr. Khan outlined NGS testing: germline (blood/saliva) for risk, somatic (tissue/CtDNA) for treatment; combine biospecimens to guide care.
Dr. McConkey highlighted liquid biopsies: CtDNA (plasma) tracks metastases, utDNA (urine) local disease; timing, levels, and clearance predict outcomes.
The panel discussed liquid biopsy/CtDNA limits and promise: need more data, better sensitivity, repeat testing, and AI integration to guide therapy decisions.
Target Audience
Physicians
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Speakers and Panelists:
Kerry Schaffer, MD
E. David Crawford, MD
Hiba Khan, MD, MPH
David J. McConkey, PhD
David M. Albala, MD
Date of Release
March 20th, 2026
%2016.47.03-1770752981975.webp&w=3840&q=75)
